Showing 2371-2380 of 4063 results for "".
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat
- New World Medical Launches Ahmed ClearPath Glaucoma Drainage Devicehttps://modernod.com/news/new-world-medical-launches-ahmed-clearpath-glaucoma-drainage-device/2476814/New World Medical announced the launch of the Ahmed ClearPath glaucoma drainage device, which is available in two sizes, 350 mm2 and 250 mm.2 A unique feature of the Ahmed ClearPath implant is a flexible plate with a contour that closely conforms to the curvature of the eye
- FDA Approves Eylea Injection Prefilled Syringehttps://modernod.com/news/fda-approves-eylea-injection-prefilled-syringe/2476803/Regeneron Pharmaceuticals announced that the FDA has approved Eylea (aflibercept) Injection prefilled syringe. The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials. The approval was made
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- New Age-Related Macular Degeneration Common in Untreated Fellow Eyeshttps://modernod.com/news/new-age-related-macular-degeneration-common-in-untreated-fellow-eyes/2476748/New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies, as reported b
- Brits in the Dark Over Eye Health According to Orbis UKhttps://modernod.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/New research reveals that over half of Brits (53%) do not get their eyes tested every 2 years as recommended, and just over 1 in 10 (11%) can’t remember the last time they went to the optician. This is despite 45% of those surveyed listing sight as their most valuable sense. The surv
- Watchful Waiting OK in Diabetic Macular Edema With Good Visionhttps://modernod.com/news/watchful-waiting-ok-in-diabetic-macular-edema-with-good-vision/2476573/Among patients with center-involved diabetic macular edema (DME) who had good visual acuity, there were no significant differences in vision loss over a 2-year period for those who were initially managed with watchful waiting as compared with those who underwent treatment with laser photocoagulat
- Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRShttps://modernod.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/Eyenovia announced the safety and efficacy results from the company’s two phase 3 trials, MIST-1 and MIST-2, for pharmacologic mydriasis (pupil dilation). The results were presented by David Wirta, MD, from the podium during the joint ASCRS-ASOA annual meeting, on May 5, 2019 in S
- Johnson & Johnson Vision Showcases the Rising Burden of Myopia, New Contact Lens and Surgical Technologies at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-the-rising-burden-of-myopia-new-contact-lens-and-surgical-technologies-at-arvo/2476549/Johnson & Johnson Vision showcased new research abstracts covering topics across a range of eye health needs at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) in Vancouver, Canada, April 28-May 2, 2019. Presentations included the first predictive model for dire